We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
News

Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022

Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022
News

Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Discovery Announces the Initiation of a Phase II Clinical Trial with ADC4022"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Argenta Discovery Ltd, the respiratory drug discovery and development company, announces that it has initiated a Phase II clinical trial with ADC4022 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and steroid-insensitive asthma.

The Phase II study is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate the effect of inhaled ADC4022 and an inhaled corticosteroid on markers of inflammation and pulmonary function. The study will involve patients with moderate to severe COPD treated over a 4 week period.

Commenting on the clinical study, Dr Mary Fitzgerald, Argenta Discovery’s Executive VP of Respiratory, said, “This novel combination approach has the potential to revolutionize the treatment of COPD and steroid insensitive asthma, as it is expected to restore steroid sensitivity of these severe and debilitating respiratory diseases and, therefore, provide enhanced disease control for patients.

Dr Christopher Ashton, Argenta Discovery’s CEO commented, “This is a very exciting time for Argenta.  We are particularly pleased to have initiated our Phase II trial with world class investigators and we look forward to the results of this study later this year.”

Advertisement